Physician profile
Nathan A Graves
NPI 1992705768
$3,772.54
in general payments reported to CMS, 2019-2025
38 companies · $67.39 in 2025
The $67.39 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.69 · 2020: $685 · 2021: $1,108 · 2022: $850 · 2023: $710 · 2024: $335 · 2025: $67.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,111.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $572.02 | 2020-2024 | |
| Novo Nordisk INC | $490.09 | 2020-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $434.32 | 2020-2023 | Jardiance, Emgality |
| Glaxosmithkline, LLC. | $352.94 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $233.43 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.77 | 2020-2024 | Jardiance |
| Pfizer INC. | $181.98 | 2020-2024 | |
| Medtronic, INC. | $142.92 | 2022 | |
| Amgen INC. | $131.00 | 2020-2023 | Repatha, Otezla |
| Abbott Laboratories | $108.64 | 2023-2024 | Proclaim, Freestyle Libre 3 |
| Exact Sciences Corporation | $86.42 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $84.06 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $74.48 | 2020-2021 | |
| Astellas Pharma US INC | $63.24 | 2020-2021 | |
| Amarin Pharma, INC. | $55.13 | 2020-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $55.02 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.84 | 2020 | |
| Corcept Therapeutics | $41.88 | 2021 | |
| Allergan, INC. | $36.35 | 2020 | |
| Coloplast Corp | $36.32 | 2023 | Speedicath |
| Ibsa Pharma INC. | $33.59 | 2020-2021 | |
| Ucb, INC. | $26.65 | 2023 | Fintepla |
| Biohaven Pharmaceutical Holding Company LTD. | $24.04 | 2022 | |
| Gilead Sciences, INC. | $21.88 | 2021 | |
| Olympus America INC. | $20.55 | 2023 | Itind System |
| Antares Pharma, INC. | $19.84 | 2023 | Xyosted, Nocdurna, Tlando |
| Neotract INC. | $17.69 | 2019 | |
| Xeris Pharmaceuticals, INC. | $17.12 | 2023 | Gvoke Hypopen |
| Blue Earth Diagnostics | $16.34 | 2025 | Posluma |
| Merck Sharp & Dohme LLC | $16.23 | 2021 | |
| Halozyme INC | $16.04 | 2023 | |
| Horizon Therapeutics Plc | $14.54 | 2020 | |
| Janssen Pharmaceuticals, INC | $14.50 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.94 | 2021 | |
| Bardy Diagnostics, INC. | $12.88 | 2022 | |
| Urovant Sciences INC | $11.58 | 2021 | |
| Laborie Medical Technologies Corp. | $11.50 | 2025 | |
| Althera Pharmaceuticals LLC | $9.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Graves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.